Jabbarli, R.; Ahmadipour, Y.; Rauschenbach, L.; Santos, A.N.; Darkwah Oppong, M.; Pierscianek, D.; Quesada, C.M.; Kebir, S.; Dammann, P.; Guberina, N.;
et al. How about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis. Cancers 2021, 13, 3770.
https://doi.org/10.3390/cancers13153770
AMA Style
Jabbarli R, Ahmadipour Y, Rauschenbach L, Santos AN, Darkwah Oppong M, Pierscianek D, Quesada CM, Kebir S, Dammann P, Guberina N,
et al. How about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis. Cancers. 2021; 13(15):3770.
https://doi.org/10.3390/cancers13153770
Chicago/Turabian Style
Jabbarli, Ramazan, Yahya Ahmadipour, Laurèl Rauschenbach, Alejandro N. Santos, Marvin Darkwah Oppong, Daniela Pierscianek, Carlos M. Quesada, Sied Kebir, Philipp Dammann, Nika Guberina,
and et al. 2021. "How about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis" Cancers 13, no. 15: 3770.
https://doi.org/10.3390/cancers13153770
APA Style
Jabbarli, R., Ahmadipour, Y., Rauschenbach, L., Santos, A. N., Darkwah Oppong, M., Pierscianek, D., Quesada, C. M., Kebir, S., Dammann, P., Guberina, N., Scheffler, B., Kaier, K., Stuschke, M., Sure, U., & Wrede, K. H.
(2021). How about Levetiracetam in Glioblastoma? An Institutional Experience and Meta-Analysis. Cancers, 13(15), 3770.
https://doi.org/10.3390/cancers13153770